COVID-19 COVID-19 SARS-CoV2
Conditions
Interventions
Mefenamic acid (Experimental group): Mefenamic acid in tablets, 500mg (orally) every 8 hours for 7 days. Moreover, the patient will receive usual treatment consisting of Paracetamol 500 mg (orally) ev
Acetaminophen
Omeprazole
Placebos
Tablets
Administration, Oral
Sponsors
Medical School of the University of Colima, Mexico
General Hospital of Zone 1, Mexican Institute of Social Security (IMSS-Colima), Mexico
Cancerology State Institute, Colima State Health Service (SSA-Colima), Mexico
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Outpatients treated at home (without pneumonia and with peripheral blood oxygen saturation equal to or greater than 90% breathing ambient air): 1. Patients diagnosed with COVID-19, with uncomplicated disease. 2. Age: 18 years - 85 years old. 3. Acceptance in writing, with prior information.
Exclusion criteria
Exclusion criteria: 1. Rheumatoid arthritis. 2. Autoimmune diseases. 3. Previously diagnosed cardiac diseases (ischemic). 4. Chronic decompensated systemic disease prior to the diagnosis of COVID-19. 5. Creatinine 1.25 times higher than the normal value or creatinine clearance less than 50 milliliters / minute (Cockfrot and Gault method), prior to the diagnosis of COVID-19. 6. Blood hemoglobin less than 10g / Dl, prior to the diagnosis of COVID-19. 7. Increase in the last month of diastolic blood pressure to 110 mmHg or more and / or appearance of hematuria or proteinuria greater than 300 milligrams / day. 8. Intestinal pseudo-obstruction. Defined as abdominal pain, with airborne levels on radiographs of the AP abdomen and lateral foot. 9. Pregnant and lactating women. 10. Drug addiction (illicit drugs). 11. Known liver disease prior to the diagnosis of COVID-19 with a doubling of liver function tests (Aspartatoamine transferase (AST), Alaninoamine transferase (ALT), Alkaline phosphatase, Bilirubins). 12. Presence of Cancer. 13. Other pathologies at the discretion of the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acceptable symptom status of the patient. (Days to reach a state of acceptable symptoms, determined as the number of days that elapsed from the start of treatment until the patient answered with a "Yes" to the following question: "Considering all the different ways your disease is affecting you, if you were to stay in this state for the next few months, do you consider that your current state is satisfactory? ”: Yes or No.) Measurement time: Daily, from patient randomization (baseline) to day 20. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse Events-AE (Present or Absent. AE will be classified according to the "Common Terminology Criteria for Adverse Events (CTCAE) version 5). Measurement time: Daily until 20th day or until patient outcome (cure or death). 2. Change in laboratory test values (Dimero D, C-reactive protein, fibrinogen and erythrocyte sedimentation rate). Measurement time: Basal, at 2, 4, 6 and 14 days. | — |
Countries
Mexico
Contacts
Public ContactJose Guzman-Esquivel
General Hospital of Zone 1, Mexican Institute of Social Security (IMSS-Colima), Mexico.
Outcome results
None listed